StreetAlpha.app
Home › Stocks › DRTS

Alpha Tau Medical Ltd. (DRTS)

Healthcare
$12.09
▲ +1.00%
LAST CLOSE · NOV 17

Alpha Tau Medical develops Alpha DaRT, a localized radiation therapy technology for solid tumors. It last closed at $12.09 on Nov 17, up 1.00% on the day. DRTS reports earnings on Thu, Nov 19, 2026. The average 12-month price target from 3 analysts is $22.67 (+87.5% from the last close), with a high of $30.00 and a low of $16.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).

AI Auto Pilots
Is DRTS in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$42.6M
Free cash flow
−$32.8M
Balance sheet
Cash & equivalents
$12.2M
At Dec 31
Shareholder equity
$77.1M
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$27.3M−$27.3MFY2021FY2022: −$33.8M−$33.8MFY2022FY2023: −$29.2M−$29.2MFY2023FY2024: −$31.8M−$31.8MFY2024FY2025: −$42.6M−$42.6MFY2025

From DRTS's SEC filings, latest 20-F for the period ending Dec 31, 2025 (filed Mar 9). Last 12 months adds up the four latest quarters. Per share figures are left out because the US listing can represent a different number of shares.

Next report
Nov 19
2026 · Time not announced
Consensus EPS forecast
-$0.15
$125,000 revenue est.
Year-ago EPS
—
Not on file
Options-implied move
—
Posted about a week before
Analyst consensus
Strong Buy
Based on 3 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
3firms
3 Buy0 Hold0 Sell
Each firm's latest rating on DRTS in the past 90 days
Average 12-month target
$22.67
▲ 87.5% upside

Based on 3 analysts who set a price target on DRTS in the past 90 days. The average target is $22.67, with a high of $30.00 and a low of $16.00, compared with the last close of $12.09.

Low $16.00Avg $22.67High $30.00
Blue marker: last close $12.09
Highest target$30.00
Average target$22.67
Lowest target$16.00
Latest rating changes
Piper SandlerUpgrade
Nov 11Buy$22
HC Wainwright & Co.Reiterated
Oct 20Buy$16
BarclaysTarget raised
Sep 3Buy$17 → $30
HC Wainwright & Co.Target raised
Aug 11Buy$15 → $16
HC Wainwright & Co.Reiterated
Jul 16Buy$15
DateFirmActionRatingPrice target
Nov 11Piper SandlerUpgradeBuy$22
Oct 20HC Wainwright & Co.ReiteratedBuy$16
Sep 3BarclaysTarget raisedBuy$17 → $30
Aug 11HC Wainwright & Co.Target raisedBuy$15 → $16
Jul 16HC Wainwright & Co.ReiteratedBuy$15
Loading…

Technical Analysis

DRTS · as of the Nov 17 close · updated after every close
Pullback inside a longer uptrend

The stock is 10% below its 20 day and 15% below its 50 day average. It is 9% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 38). The nearest support is the Pivot at $12.00, and the nearest resistance the Pivot R1 at $12.29.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNormal
VolatilityNormal, 6.6%/day
Key levels
$15.7952 week high+30.6%
$13.9550 day average+15.4%
$13.66100 day average+13.0%
$13.66Swing high (Oct 27)+13.0%
$13.2820 day average+9.8%
$12.29Pivot R1+1.7%
$12.09Last close
$12.00Pivot−0.7%
$11.99Swing low (Oct 16)−0.8%
$11.79Pivot S1−2.5%
$10.97200 day average−9.3%
$3.4352 week low−71.6%
Indicators
RSI (14)38.18Weak, oversold below 30Neutral
MACD-0.27Below its signal lineBearish
Stochastic18.9Near the bottom of its rangeOversold
ADX (14)20.6Weak trend
Williams %R-86.5Oversold below −80, overbought above −20Oversold
CCI (20)-237.3Oversold below −100, overbought above 100Oversold
Rate of change−10.7%Change over 10 sessionsBearish
ATR (14)$0.79Typical daily range, 6.5% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Above
What happened before, for DRTS

What happened before

See how DRTS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Earnings in 1 daySignals right before a report are less reliable. The report can override them.
November seasonalityHow DRTS usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How DRTS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in DRTS in the last 90 days.

Loading…

See today’s whale options flow across the market →

DRTS Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲58 buying vs 30 selling
  • ▲Shares held by funds +42.2%
  • ▲Funds holding +21
  • ●Superinvestors: 1 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding9574+28.4%
In funds' top 10110.0%
Held by funds–––
New / increased34 / 2426 / 18+31.8%
Reduced / sold out16 / 1410 / 6+87.5%
Put/call ratio0.03––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See DRTS institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether DRTS is in one of them and how their past DRTS trades turned out.

DRTS in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered DRTS in an article yet. Here's the latest on the wider market.

About Alpha Tau Medical

Alpha Tau Medical is based in Jerusalem, Israel, and develops Alpha DaRT, a localized radiation therapy technology for solid tumors. It uses alpha particles, which travel only short distances, to treat tumors in place. The company is running clinical trials for skin, head and neck, pancreatic and brain tumors, including cancers that are hard to remove surgically or not well served by standard care. Its intended customers are cancer patients and the hospitals and medical centers that treat them.

Headquarters
Jerusalem, Israel